These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 2579441)
1. ProMACE-MOPP combination chemotherapy for diffuse lymphomas. Fisher RI; Young RC; Longo D; DeVita VT Semin Oncol; 1985 Mar; 12(1 Suppl 2):29-32. PubMed ID: 2579441 [TBL] [Abstract][Full Text] [Related]
2. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Longo DL; Duffey PL; Jaffe ES; Raffeld M; Hubbard SM; Fisher RI; Wittes RE; DeVita VT; Young RC J Clin Oncol; 1994 Oct; 12(10):2153-9. PubMed ID: 7523607 [TBL] [Abstract][Full Text] [Related]
3. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442 [TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
5. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis. Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406 [TBL] [Abstract][Full Text] [Related]
6. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144 [TBL] [Abstract][Full Text] [Related]
7. [ProMACE-MOPP vs. ProMACE-CytaBOM polychemotherapies in the treatment of large-cell and unclassifiable non-Hodgkin's lymphomas]. Pieresca C; Gobbi PG; Bertoloni D; Grignani G; Rossi A; Legnani MC; Giordano M Ann Ital Med Int; 1991; 6(3):267-72. PubMed ID: 1723289 [TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies. Anderson KC; Skarin AT; Rosenthal DS; MacIntyre JM; Pinkus GS; Case DC; Leonard RC; Canellos GP Cancer Treat Rep; 1984 Nov; 68(11):1343-50. PubMed ID: 6209007 [TBL] [Abstract][Full Text] [Related]
9. ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma. Prokocimer M; Modan M; Rusoshansky S; Bairey O; Shaklai M Anticancer Res; 1989; 9(4):1233-5. PubMed ID: 2479327 [TBL] [Abstract][Full Text] [Related]
10. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V; J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249 [TBL] [Abstract][Full Text] [Related]
11. ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG). Chisesi T; Santini G; Capnist G; Coser P; Contu A; Porcellini A; Rizzoli V; Sertoli M; Rancan L; Salvagno L Leukemia; 1991; 5 Suppl 1():107-11. PubMed ID: 1716334 [TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy for non-Hodgkin's lymphoma]. Kuraishi Y; Usui N; Dobashi N Gan To Kagaku Ryoho; 1998 Dec; 25(14):2210-6. PubMed ID: 9881077 [TBL] [Abstract][Full Text] [Related]
13. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL). Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814 [TBL] [Abstract][Full Text] [Related]
14. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Miller TP; Dana BW; Weick JK; Jones SE; Coltman CA; Dahlberg S; Fisher RI Semin Hematol; 1988 Apr; 25(2 Suppl 2):17-22. PubMed ID: 2456619 [TBL] [Abstract][Full Text] [Related]